AHMED NADIM 4

What Happened
Ahmed Nadim, President & CEO and a director of Cullinan Therapeutics (CGEM), sold 16,381 shares in an open-market/private sale on February 20, 2026. The shares were sold at $13.62 each for total gross proceeds of about $223,109. This was a sale (not a purchase), and the filing indicates the transaction was to satisfy personal tax obligations related to vesting restricted stock units.

Key Details

• Transaction date: 2026-02-20; Type: Sale (code S)
• Price: $13.62 per share; Shares sold: 16,381; Gross proceeds ≈ $223,109
• Footnote: Sale made to cover personal income tax obligations upon RSU vesting (tax withholding)
• Filing date: Form 4 filed 2026-02-23 (filed within the required reporting window)
• Shares owned after the transaction: Not specified in the provided filing excerpt

Context
This sale was entered as tax withholding following RSU vesting, a common and routine reason for insider sales that does not necessarily signal a change in the insider’s view on the company. Purchases by insiders tend to be more indicative of bullish sentiment; routine tax-related sales are usually neutral from an informational standpoint.